195 related articles for article (PubMed ID: 31255992)
1. Prognostic immunohistochemical biomarkers of chemotherapy efficacy in biliary tract cancer: A systematic review and meta-analysis.
Belkouz A; Labeur TA; Dierks J; Dijk F; van Oijen MGH; Verheij J; van Gulik TM; van de Vijver MJ; Wilmink H; Punt CJA; Klümpen HJ
Crit Rev Oncol Hematol; 2019 Sep; 141():82-94. PubMed ID: 31255992
[TBL] [Abstract][Full Text] [Related]
2. Excision repair cross-complementing gene-1, ribonucleotide reductase subunit M1, ribonucleotide reductase subunit M2, and human equilibrative nucleoside transporter-1 expression and prognostic value in biliary tract malignancy.
Fisher SB; Fisher KE; Patel SH; Lim MG; Kooby DA; El-Rayes BF; Staley CA; Adsay NV; Farris AB; Maithel SK
Cancer; 2013 Jan; 119(2):454-62. PubMed ID: 22760605
[TBL] [Abstract][Full Text] [Related]
3. Prognostic predictive values of gemcitabine sensitivity-related gene products for unresectable or recurrent biliary tract cancer treated with gemcitabine alone.
Murata A; Amano R; Yamada N; Kimura K; Yashiro M; Nakata B; Hirakawa K
World J Surg Oncol; 2013 May; 11():117. PubMed ID: 23710668
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine sensitivity factors, hENT1 and RRM1 as potential prognostic biomarker for advanced biliary tract cancer.
Deng T; Pan H; Han R; Huang D; Li H; Zhou L; Wang X; Bai M; Li X; Liu R; Ge S; Ning T; Zhang L; Ba Y
Int J Clin Exp Med; 2014; 7(12):5041-9. PubMed ID: 25664003
[TBL] [Abstract][Full Text] [Related]
5. Concurrent analysis of human equilibrative nucleoside transporter 1 and ribonucleotide reductase subunit 1 expression increases predictive value for prognosis in cholangiocarcinoma patients treated with adjuvant gemcitabine-based chemotherapy.
Sasaki H; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Kondo N; Sueda T
Br J Cancer; 2014 Sep; 111(7):1275-84. PubMed ID: 25032731
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme.
Moehler M; Maderer A; Schimanski C; Kanzler S; Denzer U; Kolligs FT; Ebert MP; Distelrath A; Geissler M; Trojan J; Schütz M; Berie L; Sauvigny C; Lammert F; Lohse A; Dollinger MM; Lindig U; Duerr EM; Lubomierski N; Zimmermann S; Wachtlin D; Kaiser AK; Schadmand-Fischer S; Galle PR; Woerns M;
Eur J Cancer; 2014 Dec; 50(18):3125-35. PubMed ID: 25446376
[TBL] [Abstract][Full Text] [Related]
7. Human equilibrative nucleoside transporter 1 (hENT1) expression as a predictive biomarker for gemcitabine chemotherapy in biliary tract cancer.
Kim J; Kim H; Lee JC; Kim JW; Paik WH; Lee SH; Hwang JH; Ryu JK; Kim YT
PLoS One; 2018; 13(12):e0209104. PubMed ID: 30557411
[TBL] [Abstract][Full Text] [Related]
8. Ribonucleotide reductase subunit M1 assessed by quantitative double-fluorescence immunohistochemistry predicts the efficacy of gemcitabine in biliary tract carcinoma.
Nakamura J; Kohya N; Kai K; Ohtaka K; Hashiguchi K; Hiraki M; Kitajima Y; Tokunaga O; Noshiro H; Miyazaki K
Int J Oncol; 2010 Oct; 37(4):845-52. PubMed ID: 20811706
[TBL] [Abstract][Full Text] [Related]
9. RRM1 Expression as a Prognostic Biomarker for Unresectable or Recurrent Biliary Tract Cancer Treated with Gemcitabine plus Cisplatin.
Chun JW; Lee B; Park WS; Han N; Hong EK; Park EY; Han SS; Park SJ; Kim TH; Lee WJ; Woo SM
J Clin Med; 2021 Oct; 10(20):. PubMed ID: 34682775
[TBL] [Abstract][Full Text] [Related]
10. Orotate phosphoribosyltransferase as a predictor of benefit from S-1 adjuvant chemotherapy for cholangiocarcinoma patients.
Akahoshi K; Ban D; Kuboki R; Oba A; Ono H; Mitsunori Y; Kudo A; Tanaka S; Tanabe M
J Gastroenterol Hepatol; 2019 Jun; 34(6):1108-1115. PubMed ID: 30242888
[TBL] [Abstract][Full Text] [Related]
11. Cytidine Deaminase as a Molecular Predictor of Gemcitabine Response in Patients with Biliary Tract Cancer.
Yoon KA; Woo SM; Hong EK; Jung MK; Park WS; Bae K; Han SS; Kim TH; Koh YH; Park SJ; Lee WJ
Oncology; 2015; 89(6):345-50. PubMed ID: 26418006
[TBL] [Abstract][Full Text] [Related]
12. Human equilibrative nucleoside transporter 1 (hENT1) levels predict response to gemcitabine in patients with biliary tract cancer (BTC).
Santini D; Schiavon G; Vincenzi B; Cass CE; Vasile E; Manazza AD; Catalano V; Baldi GG; Lai R; Rizzo S; Giacobino A; Chiusa L; Caraglia M; Russo A; Mackey J; Falcone A; Tonini G
Curr Cancer Drug Targets; 2011 Jan; 11(1):123-9. PubMed ID: 20578980
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of uracil-tegafur plus doxorubicin and prognostic factors in patients with unresectable biliary tract cancer.
Furuse J; Okusaka T; Ohkawa S; Nagase M; Funakoshi A; Boku N; Yamao K; Yamaguchi T; Sato T
Cancer Chemother Pharmacol; 2009 Dec; 65(1):113-20. PubMed ID: 19404641
[TBL] [Abstract][Full Text] [Related]
14. Human equilibrative nucleoside transporter 1 (hENT1) protein is associated with short survival in resected ampullary cancer.
Santini D; Perrone G; Vincenzi B; Lai R; Cass C; Alloni R; Rabitti C; Antinori A; Vecchio F; Morini S; Magistrelli P; Coppola R; Mackey JR; Tonini G
Ann Oncol; 2008 Apr; 19(4):724-8. PubMed ID: 18187485
[TBL] [Abstract][Full Text] [Related]
15. Programmed Death Ligand 1 Expression as a Prognostic Marker in Patients with Advanced Biliary Tract Cancer.
Kim H; Kim J; Byeon S; Jang KT; Hong JY; Lee J; Park SH; Park JO; Park YS; Lim HY; Kang WK; Kim ST
Oncology; 2021; 99(6):365-372. PubMed ID: 33730723
[TBL] [Abstract][Full Text] [Related]
16. Human equilibrative nucleoside transporter 1 (hENT1) expression is a potential predictive tool for response to gemcitabine in patients with advanced cholangiocarcinoma.
Borbath I; Verbrugghe L; Lai R; Gigot JF; Humblet Y; Piessevaux H; Sempoux C
Eur J Cancer; 2012 May; 48(7):990-6. PubMed ID: 22137164
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes for previously treated patients with advanced biliary tract cancer: a meta-analysis.
Amonkar MM; Abderhalden LA; Fox GE; Frederickson AM; Grira T; Gozman A; Malhotra U; Malbecq W; Akers KG
Future Oncol; 2024 Apr; 20(13):863-876. PubMed ID: 38353044
[No Abstract] [Full Text] [Related]
18. Prognostic effect of hENT1, dCK and HuR expression by morphological type in periampullary adenocarcinoma, including pancreatic cancer.
Elebro J; Ben Dror L; Heby M; Nodin B; Jirström K; Eberhard J
Acta Oncol; 2016; 55(3):286-96. PubMed ID: 26362587
[TBL] [Abstract][Full Text] [Related]
19. Predictive and prognostic values of ERCC1 and XRCC1 in biliary tract cancers.
Mian M; McNamara MG; Doherty M; Hedley D; Knox JJ; Serra S
J Clin Pathol; 2016 Aug; 69(8):695-701. PubMed ID: 26763622
[TBL] [Abstract][Full Text] [Related]
20. ERCC1 in advanced biliary tract cancer patients treated with chemotherapy: prognostic and predictive roles.
da Costa Miranda V; Braghiroli MI; Faria LD; Siqueira SA; Sabbaga J; Hoff PM; Riechelmann RP
J Gastrointest Cancer; 2014 Mar; 45(1):80-6. PubMed ID: 24326865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
